For additional information regarding sites, contact 844-687-8522 — New York, New York

For additional information regarding sites, contact 844-687-8522 is a clinical research site located in New York, New York, United States 10022.

Crixeo Health Trust Score: 66/100 (FAIR). This profile has not yet been claimed by the site owner.

For additional information regarding sites, contact 844-687-8522 has participated in 7 clinical trials with 1 currently active.

Therapeutic areas: Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Immunoglobulin A Nephropathy.

Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc..

Sponsor Feasibility Report

Trust Score: 66/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for For additional information regarding sites, contact 844-687-8522?

For additional information regarding sites, contact 844-687-8522 has a Crixeo Trust Score of 66/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has For additional information regarding sites, contact 844-687-8522 conducted?

For additional information regarding sites, contact 844-687-8522 has 7 clinical trials on record, with 1 currently active. Their work covers Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Immunoglobulin A Nephropathy.

Is For additional information regarding sites, contact 844-687-8522 accredited by Crixeo Health?

For additional information regarding sites, contact 844-687-8522 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about For additional information regarding sites, contact 844-687-8522?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.